California’s New $11 Insulin Program Sets Powerful Precedent For National Healthcare Reform

Beginning next year, Californians living with diabetes will have access to state-branded insulin at significantly reduced prices, as announced by Governor Gavin Newsom. Starting January 1, long-acting insulin pens will be sold at pharmacies for $11 each, or $55 for a pack of five. These pens are interchangeable with glargine, a generic variant of Lantus, which helps manage blood sugar levels. The retail price for a comparable amount of Lantus is over $92, though consumer costs may vary based on insurance plans.“California proactively took action against the pharmaceutical industry’s high prices — we are now ensuring no Californian has to cut back on insulin or incur debt for their survival,” Newsom stated. Approximately 3.5 million Californians are impacted by diabetes, according to the American Diabetes Association. This initiative falls under the state's CalRx program, which aims to make prescription drugs more affordable and transparent.